Keio Innovation Initiative (KII) has made an additional investment in Heartseed, which is working on the commercialization of cardiac regenerative medicine, from a fund managed by KII. HS-001 as a regenerative medicine product in Japan and to start overseas clinical trials as soon as possible.

For details, please see the press release.
https://prtimes.jp/main/html/rd/p/000000043.000018580.html